FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964709076> ?p ?o ?g. }

• W2964709076 endingPage "1843" @default.
• W2964709076 startingPage "1832" @default.
• W2964709076 abstract "Abstract The FGFR4/FGF19 signaling axis is overactivated in 20% of liver tumors and currently represents a promising targetable signaling mechanism in this cancer type. However, blocking FGFR4 or FGF19 has proven challenging due to its physiological role in suppressing bile acid synthesis which leads to increased toxic bile acid plasma levels upon FGFR4 inhibition. An FGFR4-targeting antibody, U3-1784, was generated in order to investigate its suitability as a cancer treatment without major side effects. U3-1784 is a high-affinity fully human antibody that was obtained by phage display technology and specifically binds to FGFR4. The antibody inhibits cell signaling by competing with various FGFs for their FGFR4 binding site thereby inhibiting receptor activation and downstream signaling via FRS2 and Erk. The inhibitory effect on tumor growth was investigated in 10 different liver cancer models in vivo. The antibody specifically slowed tumor growth of models overexpressing FGF19 by up to 90% whereas tumor growth of models not expressing FGF19 was unaffected. In cynomolgus monkeys, intravenous injection of U3-1784 caused elevated serum bile acid and liver enzyme levels indicating potential liver damage. These effects could be completely prevented by the concomitant oral treatment with the bile acid sequestrant colestyramine, which binds and eliminates bile acids in the gut. These results offer a new biomarker-driven treatment modality in liver cancer without toxicity and they suggest a general strategy for avoiding adverse events with FGFR4 inhibitors." @default.
• W2964709076 created "2019-08-13" @default.
• W2964709076 creator A5005652257 @default.
• W2964709076 creator A5008452332 @default.
• W2964709076 creator A5011931484 @default.
• W2964709076 creator A5014243329 @default.
• W2964709076 creator A5014281350 @default.
• W2964709076 creator A5015284443 @default.
• W2964709076 creator A5017799131 @default.
• W2964709076 creator A5019088691 @default.
• W2964709076 creator A5027242651 @default.
• W2964709076 creator A5037117397 @default.
• W2964709076 creator A5041703937 @default.
• W2964709076 creator A5042066605 @default.
• W2964709076 creator A5045900182 @default.
• W2964709076 creator A5049905118 @default.
• W2964709076 creator A5050830835 @default.
• W2964709076 creator A5050925177 @default.
• W2964709076 creator A5052128531 @default.
• W2964709076 creator A5061324457 @default.
• W2964709076 creator A5074052910 @default.
• W2964709076 creator A5074255033 @default.
• W2964709076 creator A5075777753 @default.
• W2964709076 creator A5076409037 @default.
• W2964709076 creator A5081118215 @default.
• W2964709076 creator A5085197568 @default.
• W2964709076 creator A5085577903 @default.
• W2964709076 date "2019-10-01" @default.
• W2964709076 modified "2023-10-16" @default.
• W2964709076 title "Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity" @default.
• W2964709076 cites W1539520316 @default.
• W2964709076 cites W1965358479 @default.
• W2964709076 cites W1971837077 @default.
• W2964709076 cites W1994042177 @default.
• W2964709076 cites W2013424084 @default.
• W2964709076 cites W2014114541 @default.
• W2964709076 cites W2018441617 @default.
• W2964709076 cites W2027239974 @default.
• W2964709076 cites W2028415754 @default.
• W2964709076 cites W2038840577 @default.
• W2964709076 cites W2041451676 @default.
• W2964709076 cites W2043493714 @default.
• W2964709076 cites W2055172928 @default.
• W2964709076 cites W2056983875 @default.
• W2964709076 cites W2058212333 @default.
• W2964709076 cites W2063746351 @default.
• W2964709076 cites W2083422904 @default.
• W2964709076 cites W2092844371 @default.
• W2964709076 cites W2095943598 @default.
• W2964709076 cites W2101998219 @default.
• W2964709076 cites W2111846133 @default.
• W2964709076 cites W2124026197 @default.
• W2964709076 cites W2130787560 @default.
• W2964709076 cites W2133906003 @default.
• W2964709076 cites W2136130231 @default.
• W2964709076 cites W2146012023 @default.
• W2964709076 cites W2155185697 @default.
• W2964709076 cites W2161621338 @default.
• W2964709076 cites W2163341755 @default.
• W2964709076 cites W2164824799 @default.
• W2964709076 cites W2171990314 @default.
• W2964709076 cites W2314632338 @default.
• W2964709076 cites W2560499218 @default.
• W2964709076 cites W2787209010 @default.
• W2964709076 cites W4248872320 @default.
• W2964709076 doi "https://doi.org/10.1158/1535-7163.mct-18-0048" @default.
• W2964709076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31350344" @default.
• W2964709076 hasPublicationYear "2019" @default.
• W2964709076 type Work @default.
• W2964709076 sameAs 2964709076 @default.
• W2964709076 citedByCount "12" @default.
• W2964709076 countsByYear W29647090762020 @default.
• W2964709076 countsByYear W29647090762021 @default.
• W2964709076 countsByYear W29647090762022 @default.
• W2964709076 countsByYear W29647090762023 @default.
• W2964709076 crossrefType "journal-article" @default.
• W2964709076 hasAuthorship W2964709076A5005652257 @default.
• W2964709076 hasAuthorship W2964709076A5008452332 @default.
• W2964709076 hasAuthorship W2964709076A5011931484 @default.
• W2964709076 hasAuthorship W2964709076A5014243329 @default.
• W2964709076 hasAuthorship W2964709076A5014281350 @default.
• W2964709076 hasAuthorship W2964709076A5015284443 @default.
• W2964709076 hasAuthorship W2964709076A5017799131 @default.
• W2964709076 hasAuthorship W2964709076A5019088691 @default.
• W2964709076 hasAuthorship W2964709076A5027242651 @default.
• W2964709076 hasAuthorship W2964709076A5037117397 @default.
• W2964709076 hasAuthorship W2964709076A5041703937 @default.
• W2964709076 hasAuthorship W2964709076A5042066605 @default.
• W2964709076 hasAuthorship W2964709076A5045900182 @default.
• W2964709076 hasAuthorship W2964709076A5049905118 @default.
• W2964709076 hasAuthorship W2964709076A5050830835 @default.
• W2964709076 hasAuthorship W2964709076A5050925177 @default.
• W2964709076 hasAuthorship W2964709076A5052128531 @default.
• W2964709076 hasAuthorship W2964709076A5061324457 @default.
• W2964709076 hasAuthorship W2964709076A5074052910 @default.
• W2964709076 hasAuthorship W2964709076A5074255033 @default.
• W2964709076 hasAuthorship W2964709076A5075777753 @default.
• W2964709076 hasAuthorship W2964709076A5076409037 @default.

• next